Integration of Local and Systemic Immunity in Ovarian Cancer: Implications for Immunotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Nov 28

PMID 36439144

Authors

Alicja Rajtak

Marta Ostrowska-Lesko

Klaudia Zak

Rafal Tarkowski

Jan Kotarski

Karolina Okla

Affiliations

Soon will be listed here.

Abstract

Cancer is a disease that induces many local and systemic changes in immunity. The difficult nature of ovarian cancer stems from the lack of characteristic symptoms that contributes to a delayed diagnosis and treatment. Despite the enormous progress in immunotherapy, its efficacy remains limited. The heterogeneity of tumors, lack of diagnostic biomarkers, and complex immune landscape are the main challenges in the treatment of ovarian cancer. Integrative approaches that combine the tumor microenvironment - local immunity - together with periphery - systemic immunity - are urgently needed to improve the understanding of the disease and the efficacy of treatment. In fact, multiparametric analyses are poised to improve our understanding of ovarian tumor immunology. We outline an integrative approach including local and systemic immunity in ovarian cancer. Understanding the nature of both localized and systemic immune responses will be crucial to boosting the efficacy of immunotherapies in ovarian cancer patients.

Citing Articles

Ovarian clear cell carcinoma: open questions on the management and treatment algorithm.

Rosso R, Turinetto M, Borella F, Chopin N, Meeus P, Laine A Oncologist. 2025; 30(1).

PMID: 39846983 PMC: 11756325. DOI: 10.1093/oncolo/oyae325.

Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review.

Na J, Liu Y, Fang K, Tan Y, Liang P, Yan M Invest New Drugs. 2024; 42(6):728-738.

PMID: 39432145 DOI: 10.1007/s10637-024-01478-4.

Comprehensive in silico analysis of prognostic and immune infiltrates for FGFs in human ovarian cancer.

Wang Y, Zhang H, Zhan Y, Li Z, Li S, Guo S J Ovarian Res. 2024; 17(1):197.

PMID: 39385288 PMC: 11465590. DOI: 10.1186/s13048-024-01496-z.

Isoform-Level Transcriptome Analysis of Peripheral Blood Mononuclear Cells from Breast Cancer Patients Identifies a Disease-Associated Isoform.

celesnik H, Gorenjak M, Krusic M, Crnobrnja B, Sobocan M, Takac I Cancers (Basel). 2024; 16(18).

PMID: 39335143 PMC: 11429621. DOI: 10.3390/cancers16183171.

Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy.

Guo H, Wei J, Zhang Y, Wang L, Wan J, Wang W Genes Dis. 2024; 11(6):101158.

PMID: 39253578 PMC: 11382211. DOI: 10.1016/j.gendis.2023.101158.

References

Komdeur F, Wouters M, Workel H, Tijans A, Terwindt A, Brunekreeft K . CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget. 2016; 7(46):75130-75144. PMC: 5342728. DOI: 10.18632/oncotarget.12077. View

Bronger H, Singer J, Windmuller C, Reuning U, Zech D, Delbridge C . CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br J Cancer. 2016; 115(5):553-63. PMC: 4997538. DOI: 10.1038/bjc.2016.172. View

Henriksen J, Donskov F, Waldstrom M, Jakobsen A, Hjortkjaer M, Petersen C . Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. Acta Oncol. 2020; 59(6):652-659. DOI: 10.1080/0284186X.2019.1711173. View

Peng D, Xu T, Mason T, Wu W . A study of ovarian cancer biomarker amplification using ultrasound for early stage detection. Ultrasonics. 2013; 54(2):451-4. DOI: 10.1016/j.ultras.2013.05.014. View

Zhang X, He T, Li Y, Chen L, Liu H, Wu Y . Dendritic Cell Vaccines in Ovarian Cancer. Front Immunol. 2021; 11:613773. PMC: 7874064. DOI: 10.3389/fimmu.2020.613773. View

Zhu Y, Zhang Z, Jiang Z, Liu Y, Zhou J . CD38 Predicts Favorable Prognosis by Enhancing Immune Infiltration and Antitumor Immunity in the Epithelial Ovarian Cancer Microenvironment. Front Genet. 2020; 11:369. PMC: 7203480. DOI: 10.3389/fgene.2020.00369. View

Yuan X, Zhang J, Li D, Mao Y, Mo F, Du W . Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis. Gynecol Oncol. 2017; 147(1):181-187. DOI: 10.1016/j.ygyno.2017.07.007. View

James F, Jiminez-Linan M, Alsop J, Mack M, Song H, Brenton J . Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. BMC Cancer. 2017; 17(1):657. PMC: 5607562. DOI: 10.1186/s12885-017-3585-x. View

He Y, Zhang M, Wu X, Sun X, Xu T, He Q . High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time. PLoS One. 2013; 8(12):e79769. PMC: 3855613. DOI: 10.1371/journal.pone.0079769. View

10.

Ren F, Fan M, Mei J, Wu Y, Liu C, Pu Q . Interferon-γ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment. Drug Des Devel Ther. 2014; 8:1527-38. PMC: 4181549. DOI: 10.2147/DDDT.S66302. View

11.

Borella F, Ghisoni E, Giannone G, Cosma S, Benedetto C, Valabrega G . Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. Diagnostics (Basel). 2020; 10(3). PMC: 7151145. DOI: 10.3390/diagnostics10030146. View

12.

Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F . Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer. 2007; 122(1):91-9. DOI: 10.1002/ijc.23083. View

13.

Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T . Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat. 2013; 12(3):259-67. DOI: 10.7785/tcrt.2012.500312. View

14.

Alsina-Sanchis E, Figueras A, Lahiguera A, Vidal A, Casanovas O, Graupera M . The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels. Int J Cancer. 2016; 139(8):1894-903. DOI: 10.1002/ijc.30233. View

15.

Clarke-Pearson D . Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009; 361(2):170-7. DOI: 10.1056/NEJMcp0901926. View

16.

Peper J, Bosmuller H, Schuster H, Guckel B, Horzer H, Roehle K . HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. Oncoimmunology. 2016; 5(5):e1065369. PMC: 4910750. DOI: 10.1080/2162402X.2015.1065369. View

17.

Colombo N, Sessa C, Bois A, Ledermann J, McCluggage W, McNeish I . ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019; 29(4):728-760. DOI: 10.1136/ijgc-2019-000308. View

18.

Uppendahl L, Dahl C, Miller J, Felices M, Geller M . Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review. Front Immunol. 2018; 8:1825. PMC: 5760535. DOI: 10.3389/fimmu.2017.01825. View

19.

El Bairi K, Al Jarroudi O, Afqir S . Inexpensive Systemic Inflammatory Biomarkers in Ovarian Cancer: An Umbrella Systematic Review of 17 Prognostic Meta-Analyses. Front Oncol. 2021; 11:694821. PMC: 8495411. DOI: 10.3389/fonc.2021.694821. View

20.

Kallies A, Zehn D, Utzschneider D . Precursor exhausted T cells: key to successful immunotherapy?. Nat Rev Immunol. 2019; 20(2):128-136. DOI: 10.1038/s41577-019-0223-7. View